The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

The ODD programme incentivises the development of medicines for conditions affecting fewer than 200,000 individuals in the US ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...

Follicle-stimulating hormone (FSH), a glycoprotein secreted by gonadotroph cells of the anterior pituitary, is classically ...

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...

Aldeyra has since resubmitted its application, buffing it up with a “single clinical trial that achieved the primary endpoint ...

These 52-week data reinforce HTD1801's potential as a truly differentiated therapeutic to concurrently address metabolic dysregulation, inflammation, and renal progression in type 2 diabetes ...

IND opening marks culmination of partnership between Dewpoint and Evotec, advancing a de novo development candidate through ...

Newron Pharmaceuticals SpA ((NWPHF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing ...

First orphan designation ever granted to a condensate-modulating therapeutic Builds on recent IND opening for DPTX3186, a first-in-class oral ...